PegBio Co., Ltd. (PegBio) announced that its core product Visepegenatide injection (trade name: Paidakang®) has been placed on the National Healthcare Security Administration’s list of drugs that have “passed the preliminary review” for the 2026 National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug List (NRDL) adjustment.
\n\nKey Details • Listing: Visepegenatide appears as Item 242 under “Western Medicines and Chinese Patent Medicines Not Included in the Catalogue – Basic Catalogue.” • Category: Classified as a western medicine; identified as an exclusive product. • Qualification: Met “Condition 1 for Drugs Not Included in the Catalogue,” enabling progression to subsequent expert review and negotiation stages.
\n\nStrategic Significance Visepegenatide is a long-acting GLP-1 receptor agonist for adult type 2 diabetes mellitus. Approved by the National Medical Products Administration in 2025, it is PegBio’s first innovative drug to reach the market, anchoring the company’s shift from research focus to commercial operations. Passing the NRDL preliminary review is a pivotal step toward broader reimbursement coverage. If ultimately listed, the drug stands to benefit from: • Improved patient affordability through insurance reimbursement. • Expanded clinical utilization across China’s diabetic population. • Enhanced commercial traction, positively affecting revenue and cash-flow generation.
\n\nNext Steps The product now advances to formal expert review and pricing negotiations with the NHSA. Final inclusion, reimbursement scope and payment standards remain contingent on NHSA’s forthcoming determinations. PegBio plans to continue aligning with clinical value and pharmacoeconomic requirements to secure full NRDL entry.
\n\nCaveat PegBio reminded shareholders and potential investors that preliminary clearance does not guarantee final NRDL inclusion; outcomes are subject to NHSA’s final announcement. The company will issue further disclosures in accordance with regulatory obligations.